PLB1004 Clinical Trials
5 recruitingDrug
Phase 24Phase 12
Showing 1–5 of 5 trials
Recruiting
Phase 2
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Avistone Biotechnology Co., Ltd.40 enrolled1 locationNCT07336732
Recruiting
Phase 1Phase 2
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Avistone Biotechnology Co., Ltd.156 enrolled1 locationNCT06343064
Recruiting
Phase 2
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Avistone Biotechnology Co., Ltd.120 enrolled1 locationNCT06574347
Recruiting
Phase 1
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.81 enrolled7 locationsNCT06046495
Recruiting
Phase 2
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Avistone Biotechnology Co., Ltd.157 enrolled1 locationNCT06015503